JPS6233208B2 - - Google Patents

Info

Publication number
JPS6233208B2
JPS6233208B2 JP51068675A JP6867576A JPS6233208B2 JP S6233208 B2 JPS6233208 B2 JP S6233208B2 JP 51068675 A JP51068675 A JP 51068675A JP 6867576 A JP6867576 A JP 6867576A JP S6233208 B2 JPS6233208 B2 JP S6233208B2
Authority
JP
Japan
Prior art keywords
udp
group
present
solution
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP51068675A
Other languages
English (en)
Japanese (ja)
Other versions
JPS52151731A (en
Inventor
Shuji Ookubo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Priority to JP6867576A priority Critical patent/JPS52151731A/ja
Publication of JPS52151731A publication Critical patent/JPS52151731A/ja
Publication of JPS6233208B2 publication Critical patent/JPS6233208B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP6867576A 1976-06-14 1976-06-14 Tumor-inhibitory composition Granted JPS52151731A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP6867576A JPS52151731A (en) 1976-06-14 1976-06-14 Tumor-inhibitory composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6867576A JPS52151731A (en) 1976-06-14 1976-06-14 Tumor-inhibitory composition

Publications (2)

Publication Number Publication Date
JPS52151731A JPS52151731A (en) 1977-12-16
JPS6233208B2 true JPS6233208B2 (cs) 1987-07-20

Family

ID=13380519

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6867576A Granted JPS52151731A (en) 1976-06-14 1976-06-14 Tumor-inhibitory composition

Country Status (1)

Country Link
JP (1) JPS52151731A (cs)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5645449A (en) * 1979-07-31 1981-04-25 Fujisawa Pharmaceut Co Ltd Novel peptide, its pharmaceutically acceptable salt and preparation of the same
DK156252C (da) * 1979-07-31 1989-12-18 Fujisawa Pharmaceutical Co Analogifremgangsmaade til fremstilling af di-, tri- eller tetrapeptidderivater eller salte deraf
AU5563699A (en) * 1998-08-20 2000-03-14 Incara Pharmaceuticals Corp. Analogs of udp-murnac peptides, assays and kits

Also Published As

Publication number Publication date
JPS52151731A (en) 1977-12-16

Similar Documents

Publication Publication Date Title
US4690918A (en) Use of trichostatin compounds for treating tumor cells
Creighton et al. Antitumour activity in a series of bis diketopiperazines
JPS6156134A (ja) コラ−ゲン性医薬組成物
US5049396A (en) Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer sensitive to treatment
JPH07501534A (ja) ガンの治療のためのクレアチンホスフェート又はホスホエノールピルビン酸の使用
JPS6233208B2 (cs)
Chirigos et al. Effectiveness of Cytoxan against intracerebrally and subcutaneously inoculated mouse lymphoid leukemia L1210
De Bast et al. Bleomycin in mycosis fungoides and reticulum cell lymphoma
US4343799A (en) Use of derivatives of 6α-methylprednisolone for the prevention or reduction of adriamycin-induced cardiotoxicity
JPS60501408A (ja) 酸化剤ストレス誘導抗生物質に対する動物許容度を増加させる方法及び薬剤
Kassel et al. Interferon-mediated oncolysis in spontaneous murine leukemia
Hagenbeek et al. BCG treatment of residual disease in acute leukemia: studies in a rat model for human acute myelocytic leukemia (BNML)
US5710179A (en) Antitumor agent
Carpenter et al. Chemotherapy of murine leprosy
JPS6233209B2 (cs)
JPH04502901A (ja) シーピーエフペプチド組成物およびその用途
Yamasaki et al. Reduction of hepatic metastases in rabbits by administration of an oily anticancer agent into the portal vein
WO2000043403A1 (en) 2-methyl-3-butenyl-1-pyrophosphoric acid salts and agents for treating lymphocytes
CN114901643B (zh) 化合物l-赖氨酸-9-氧代吖啶基-10-乙酸盐
JP3022915B2 (ja) 癌転移抑制剤
RU2165761C1 (ru) Способ лечения экспериментального туберкулеза
Jackson Treatment of superficial epitheliomatosis with an ointment containing demecolcin
Nagler Treatment of experimental gas gangrene due to Clostridium welchii with penicillin and antitoxin
Grogan Pseudomonas aeruginosa infection in mice after treatment with cyclophosphamide
Takeuchi et al. Effect of Pluramycin A on Ehrlich Carcinoma of Mice Studies on Antitumor Substance Produced by Actinomycetes. XII